Limited Predictive Value of Achieving Beneficial Plasma (Z)-Endoxifen Threshold Level by CYP2D6 Genotyping in Tamoxifen-Treated Polish Women With Breast Cancer

BMC Cancer - United Kingdom
doi 10.1186/s12885-015-1575-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated With Tamoxifen

Frontiers in Pharmacology
Pharmacology
2017English

Pcn191 - Cost-Effectiveness of Monitoring Endoxifen Levels in Breast Cancer Patients Adjuvantly Treated With Tamoxifen

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

CYP2D6 Genotyping and Tamoxifen in the Treatment of Post-Menopausal Breast Cancer - A Reply

British Journal of Clinical Pharmacology
Pharmacology
2014English

Comprehensive CYP2D6 Genotype and Adherence Affect Outcome in Breast Cancer Patients Treated With Tamoxifen Monotherapy

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Pharmaceuticals
Molecular MedicinePharmaceutical Science
2010English

Pharmacogenetics and Breast Cancer Endocrine Therapy: CYP2D6 as a Predictive Factor for Tamoxifen Metabolism and Drug Response?

Expert Reviews in Molecular Medicine
Molecular MedicineMolecular Biology
2008English

Tamoxifen Alters the Plasma Concentration of Molecules Associated With Cardiovascular Risk in Women With Breast Cancer Undergoing Chemotherapy

Oncologist
Cancer ResearchMedicineOncology
2012English

Pap Smear Results of Women With Breast Cancer Using Tamoxifen Therapy

Istanbul Medical Journal
2016English

Ovarian Cysts in Women Receiving Tamoxifen for Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy